Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic vs autologous mesenchymal stem cells vs hyaluronic acid in knee osteoarthritis
2024-514545-11-00Phase 3Authorised
- Sponsor
- Fundación de Investigación Biomédica de Salamanca
- Start
- Nov 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of autologous bone marrow derived mesenchymal stromal cells, allogeneic bone marrow-derived mesenchymal stromal cells and hyaluronic acid in knee osteoarthritis (OA) (3 arms), sponsored by Fundación de Investigación Biomédica de Salamanca. Primary endpoints: Pain intensity on VAS at 12 months, Lequesne index at 12 months and 2 more. Planned start Nov 2024; status: authorised.
02
Drugs
autologous bone marrow derived mesenchymal stromal cellsallogeneic bone marrow-derived mesenchymal stromal cellshyaluronic acid
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2024-514545-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514545-11-00.